PharmaShots | Incisive News in 3 Shots

Subscribe Now

RemeGen

RemeGen Reports the First Patient Enrollment in the P-III Study of Telitacicept to Treat Myasthenia Gravis

RemeGen Reports the First Patient Enrollment in the P-III Study of Telitacicept to Treat Myasthenia Gravis

August 6, 2024

The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer

January 12, 2024

RemeGen Reports the Result of Disitamab Vedotin (RC48) in the P-II trial for the Treatment of Urothelial Carcinoma

RemeGen Reports the Result of Disitamab Vedotin (RC48) in the P-II trial for the Treatment of Urothelial Carcinoma

November 28, 2023

RemeGen Published P-II Clinical Study Results of Telitacicept for Primary Sjogren's Syndrome in Rheumatology Journal

RemeGen Published P-II Clinical Study Results of Telitacicept for Primary Sjogren's Syndrome in Rheumatology Journal

July 25, 2023

RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for Advanced Solid Tumors

RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for A...

July 10, 2023

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

March 11, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us